Steve Aselage

Mr. Aselage has more than 30 years of pharmaceutical and biotechnology experience, most recently serving as Chief Executive Officer of Travere Therapeutics (TVTX) (formerly Retrophin, Inc.) from 2014 to 2019. Previously, he was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc.